Clinical Review

Fortnightly review

Anticoagulation in heart disease

BMJ 1999; 318 doi: 10.1136/bmj.318.7178.238 (Published 23 January 1999)
Cite this as: BMJ 1999;318:238.1

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Suzanna M C Hardman, senior lecturer in cardiology with an interest in community cardiologya,
  2. Martin R Cowie, senior lecturer in cardiologyb
  1. aAcademic and Clinical Department of Cardiovascular Medicine, University College London Medical School (Whittington Campus), St Mary's Wing, Whittington Hospital, London N19 5NF
  2. bDepartment of Medicine and Therapeutics, Polwarth Building, University of Aberdeen, Aberdeen AB25 2ZD
  1. Correspondence to: Dr Hardman

    Thromboembolism is a common complication of heart disease. The decision to prescribe an anticoagulant to prevent thromboemboli should be based on a particular patient's risk without treatment and the likely benefit and side effects of the proposed treatment. In this article we will discuss the use of warfarin and heparin in patients with heart disease.

    Summary points

    • Whether anticoagulant treatment should be started depends on the balance between the risk of thromboemboli without treatment and the likely benefits of treatment in each patient

    • Factors increasing the risk of bleeding include serious concomitant disease, previous gastrointestinal bleeding, uncontrolled hypertension, and immobility

    • Factors that cumulatively increase the risk of thromboembolism in non-rheumatic atrial fibrillation include age over 60,recent congestive heart failure, hypertension (treated or untreated), previous thromboembolism, and the presence of a large atrium or of global left ventricular dysfunction

    • Cardioversion of non-rheumatic atrial fibrillation (including fibrillation of new onset) is associated with an increased thromboembolic risk, which is reduced by anticoagulant treatment

    • Heparin and aspirin are both beneficial in unstable angina

    • Anticoagulants should be considered after myocardial infarction in patients with an increased risk of thromboemboli: patients in atrial fibrillation and those with persistent heart failure

    Methods

    This review article is based on our chapter in Current Issues in Cardiology, which was subject to formal peer review and published in 1997.1 We undertook a full Medline search in each of the relevant subjects. We also sought references from recent papers, editorials, and review articles. When a choice was available we chose large well conducted double blind randomised trials, but we included observational series when they were the only available evidence.

    Non-rheumatic atrial fibrillation

    Atrial fibrillation is not benign and is the commonest cause of cardiogenic stroke (fig 1).2 Within the general population the best available estimates suggest a prevalence of 0.5% for those …

    Access to the full text of this article requires a subscription or payment

    Subscribe

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    Rapid responses

    THIS WEEK'S POLL

    BMJ most popular